Hims & Hers Health Registered (A) WKN: A2QMYY ISIN: US4330001060 Forum: Aktien Thema: Hauptdiskussion

demnächst dann übernahme durch Amazon lol

~Dudum

We founded Hims & Hers to help more people feel great. To disrupt a broken healthcare system and create a new model of health where innovators work together to deliver access to care that actually serves everyday people. We align how we operate with where we see major growth opportunities and in a way that allows us to meet our customers where they are (and where they want to go). That’s why, later this month, Hims & Hers customers will have access to FDA-approved medications from @novonordisk as a part of a strategic collaboration. The weight loss landscape is completely different today than it was when we first entered the category. FDA-approved GLP-1 treatments are now more accessible, with greater affordability and more flexible dosing options and form factors. These market changes are shifting consumer demand towards these branded medications. We’re moving our model forward another step with this strategic shift in our US weight loss business. This evolution will make us the largest global consumer health platform providing access to more affordable, approved medications. We will continue to innovate across our platform, keeping what’s best for consumers as our North Star. There's challenging, important work in front of us, and I've never been more excited about the path ahead. Just like we always do, Hims & Hers will rise to meet the moment.

Ok ich lege nach 😅

Lets gooo

komplette strategische neuausrichtung meiner meinung... die nächsten zahlen werden spannend... und wie die margen gegenüber compounded medikamenten ausfallen werden. und ob nicht sogar noch andere auf den zug aufspringen, zB Eli Lilly

Pille kommt mit auf die Plattform und bestehende Kunden haben Zeit zu wechseln

Wir pumpen

hab doch gesagt 13:30

ENDLICH

GEIL

Das ist natürlich richtig nice.

JAAAAA

GLP-1-Compounding wird aufgegeben

Quatsch

Covering läuft mit Sicherheit nicht über den Markt sondern OTC